Purpose: To assess the alterations in bone mineral density and bone turnover marker concentrations following the administration of denosumab and romosozumab therapies in patients with osteoporosis.

Methods: PubMed was searched for studies published until January 28, 2023, that investigated the clinical efficacy and bone turnover marker changes of denosumab and romosozumab in the treatment of osteoporosis, with a minimum follow-up of 3 months in each study. Studies were screened, and data on changes in bone mineral density (BMD), P1NP, and TRACP-5b levels after treatment were extracted and included in the analysis.

Results: Six studies were analyzed. At 3 months after treatment, the romosozumab group showed greater changes in lumbar BMD and bone turnover markers. BMD of total hip and femoral neck was relatively delayed. Beginning at 6 to 12 months, romosozumab showed greater changes in bone mineral density and markers of bone turnover.

Conclusion: Both romosozumab and denosumab have antiosteoporotic effects, with greater effects on BMD and bone turnover markers observed within 12 months of romosozumab treatment.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero, identifier CRD42023395034.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390296PMC
http://dx.doi.org/10.3389/fendo.2023.1188969DOI Listing

Publication Analysis

Top Keywords

bone mineral
16
mineral density
16
bone turnover
16
denosumab romosozumab
12
turnover markers
12
bone
9
turnover marker
8
changes bone
8
greater changes
8
bmd bone
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!